An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer

• Published in: Scientific reports Vol. 7; no. 1; p. 46224
• Main Authors: Liang, Li-Guo, Kong, Meng-Qi, Zhou, Sherry, Sheng, Ye-Feng, Wang, Ping, Yu, Tao, Inci, Fatih, Kuo, Winston Patrick, Li, Lan-Juan, Demirci, Utkan, Wang, ShuQi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.04.2017; Nature Publishing Group
• Subjects: 631/67/589/1336; 692/53/2421; 82/1; Bladder cancer; Cancer; Cytology; Enzyme-linked immunosorbent assay; Exosomes; Extracellular vesicles; Filtration; Health risk assessment; Humanities and Social Sciences; Lipids; Microfluidics; multidisciplinary; Science; Ultracentrifugation; Urinary bladder; Urine
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep46224

Extracellular vesicles (EVs), including exosomes and microvesicles, are present in a variety of bodily fluids, and the concentration of these sub-cellular vesicles and their associated biomarkers (proteins, nucleic acids, and lipids) can be used to aid clinical diagnosis. Although ultracentrifugation is commonly used for isolation of EVs, it is highly time-consuming, labor-intensive and instrument-dependent for both research laboratories and clinical settings. Here, we developed an integrated double-filtration microfluidic device that isolated and enriched EVs with a size range of 30–200 nm from urine, and subsequently quantified the EVs via a microchip ELISA. Our results showed that the concentration of urinary EVs was significantly elevated in bladder cancer patients (n = 16) compared to healthy controls (n = 8). Receiver operating characteristic (ROC) analysis demonstrated that this integrated EV double-filtration device had a sensitivity of 81.3% at a specificity of 90% (16 bladder cancer patients and 8 healthy controls). Thus, this integrated device has great potential to be used in conjunction with urine cytology and cystoscopy to improve clinical diagnosis of bladder cancer in clinics and at point-of-care (POC) settings.